Tikun Olam-Cannbit Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 0/6
Tikun Olam-Cannbit Pharmaceuticals has a total shareholder equity of ₪-5.3M and total debt of ₪12.2M, which brings its debt-to-equity ratio to -227.9%. Its total assets and total liabilities are ₪24.0M and ₪29.4M respectively.
Key information
-227.94%
Debt to equity ratio
₪12.19m
Debt
| Interest coverage ratio | n/a |
| Cash | ₪160.00k |
| Equity | -₪5.35m |
| Total liabilities | ₪29.36m |
| Total assets | ₪24.01m |
Recent financial health updates
Health Check: How Prudently Does Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Use Debt?
Oct 23
Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Has Debt But No Earnings; Should You Worry?
Jun 21Would Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Be Better Off With Less Debt?
Oct 03Is Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Weighed On By Its Debt Load?
Jun 03Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Is Carrying A Fair Bit Of Debt
Oct 17Is Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Using Debt Sensibly?
May 19Recent updates
Tikun Olam-Cannbit Pharmaceuticals Ltd's (TLV:TKUN) Popularity With Investors Under Threat As Stock Sinks 26%
Dec 02Health Check: How Prudently Does Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Use Debt?
Oct 23Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Has Debt But No Earnings; Should You Worry?
Jun 21Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 28Risks To Shareholder Returns Are Elevated At These Prices For Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN)
Jul 21Would Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Be Better Off With Less Debt?
Oct 03Is Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Weighed On By Its Debt Load?
Jun 03Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Is Carrying A Fair Bit Of Debt
Oct 17Is Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Using Debt Sensibly?
May 19Shareholders Of Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Must Be Happy With Their 135% Total Return
Mar 19How Much Did Tikun Olam - Cannbit Pharmaceuticals'(TLV:TKUN) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 02
Financial Position Analysis
Short Term Liabilities: TKUN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: TKUN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: TKUN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: TKUN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TKUN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TKUN has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.2% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 23:37 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tikun Olam-Cannbit Pharmaceuticals Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.